Adams Catherine Owen
CIK: 0001816838
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectStock options (right to buy)
15K shares- - Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct2.8K shares- - Jun 18, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectRestricted stock units
2.9K shares- - Jun 13, 2026AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct2K shares- - Mar 25, 2026ACAD
ACADIA PHARMACEUTICALS INC
Sale(S)Direct11.6K shares at avg. $21.47$250K - Mar 24, 2026ACAD
ACADIA PHARMACEUTICALS INC
Exercise(M)Direct23.5K shares- - Mar 6, 2026ACAD
ACADIA PHARMACEUTICALS INC
Award(A)DirectRestricted Stock Units
76.5K shares- - Mar 6, 2026ACAD
ACADIA PHARMACEUTICALS INC
Award(A)DirectStock Option (Right to Buy)
263K shares- - Jun 20, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct2.1K shares- - Jun 18, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectStock options (right to buy)
15.8K shares- - Jun 18, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Award(A)DirectRestricted stock units
2.8K shares- - Jun 13, 2025AGIO
AGIOS PHARMACEUTICALS, INC.
Exercise(M)Direct2K shares- - Mar 24, 2025ACAD
ACADIA PHARMACEUTICALS INC
Award(A)DirectStock Option (Right to Buy)
320K shares- - Mar 24, 2025ACAD
ACADIA PHARMACEUTICALS INC
Award(A)DirectRestricted Stock Units
94K shares- - Sep 23, 2024ACAD
ACADIA PHARMACEUTICALS INC
Award(A)DirectStock Option (Right to Buy)
353.3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 18, 2026 |  AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Stock options (right to buy) | 14,950 | - | - | Direct |
| Jun 18, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 2,816 | - | $0 | Direct |
| Jun 18, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Restricted stock units | 2,927 | - | - | Direct |
| Jun 13, 2026 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 1,976 | - | $0 | Direct |
| Mar 25, 2026 |  ACAD ACADIA PHARMACEUTICALS INC | Sale(S) | 11,641 | $21.47 | $249,932 | Direct |
| Mar 24, 2026 | ACAD ACADIA PHARMACEUTICALS INC | Exercise(M) | 23,509 | - | $0 | Direct |
| Mar 6, 2026 | ACAD ACADIA PHARMACEUTICALS INC | Award(A) Restricted Stock Units | 76,509 | - | - | Direct |
| Mar 6, 2026 | ACAD ACADIA PHARMACEUTICALS INC | Award(A) Stock Option (Right to Buy) | 263,005 | - | - | Direct |
| Jun 20, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 2,120 | - | - | Direct |
| Jun 18, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Stock options (right to buy) | 15,768 | - | - | Direct |
| Jun 18, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Award(A) Restricted stock units | 2,816 | - | - | Direct |
| Jun 13, 2025 | AGIO AGIOS PHARMACEUTICALS, INC. | Exercise(M) | 1,977 | - | - | Direct |
| Mar 24, 2025 | ACAD ACADIA PHARMACEUTICALS INC | Award(A) Stock Option (Right to Buy) | 319,976 | - | - | Direct |
| Mar 24, 2025 | ACAD ACADIA PHARMACEUTICALS INC | Award(A) Restricted Stock Units | 94,039 | - | - | Direct |
| Sep 23, 2024 | ACAD ACADIA PHARMACEUTICALS INC | Award(A) Stock Option (Right to Buy) | 353,261 | - | - | Direct |
1-15 of 15 transactions
About Owen Adams Catherine
Owen Adams Catherine (SEC CIK 0001816838) files insider reports with the SEC as Director of AGIOS PHARMACEUTICALS, INC. (AGIO) and Chief Executive Officer of ACADIA PHARMACEUTICALS INC (ACAD).
Signal8 holds 9 ownership filings by Owen Adams Catherine (1 Form 3, 8 Form 4), filed between Sep 25, 2024 and Jun 23, 2026. Those filings report 15 transactions, from Sep 23, 2024 to Jun 18, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Owen Adams Catherine's filings is in CAMBRIDGE, MA.
Recent filings by Owen Adams Catherine
- Jun 18, 2026: Grant or award of AGIO derivative securities (Form 4, code A).
- Jun 18, 2026: Option exercise of AGIO shares (Form 4, code M).
- Jun 18, 2026: Grant or award of AGIO derivative securities (Form 4, code A).
- Jun 13, 2026: Option exercise of AGIO shares (Form 4, code M).
- Mar 25, 2026: Open-market sale of ACAD shares (Form 4, code S).
Other insiders filing for AGIOS PHARMACEUTICALS, INC. (AGIO)
- Gheuens Sarah, Chief Medical Officer
- Backstrom Jay T., Director
- Ballal Rahul D., Director
- CAPELLO JEFFREY D, Director
- Foster-Cheek Kaye I, Director
- FOUSE JACQUALYN A, Director